Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The dual incretin agonists segment held a 23% share of the market in 2025 and is expected to grow at a CAGR of 18.5% during the projection period
One such breakthrough is PT-141 (Bremelanotide), a peptide therapy designed to address low libido and enhance sexual arousal by targeting the brain's central mechanisms, rather than focusing on physical blood flow
It can also serve as supportive therapy in cases of inappetence
People with type 2 diabetes may take semaglutide to help control their blood sugar levels
US$ 27.58
US$ 22.98
US$ 21.17
US$ 21.61
US$ 21.64
